Victrex (LON:VCT) Lifted to Equal Weight at Barclays
Barclays upgraded shares of Victrex (LON:VCT) to an equal weight rating in a research report report published on Wednesday, Digital Look reports. Barclays currently has GBX 2,020 ($26.39) price target on the stock.
Several other brokerages have also weighed in on VCT. Credit Suisse Group reaffirmed an outperform rating and set a GBX 3,000 ($39.20) target price on shares of Victrex in a research note on Wednesday, June 5th. Liberum Capital reissued a buy rating on shares of Victrex in a research report on Thursday, July 25th. JPMorgan Chase & Co. reduced their price target on shares of Victrex from GBX 2,300 ($30.05) to GBX 2,150 ($28.09) and set a neutral rating on the stock in a research report on Friday, July 5th. Peel Hunt reissued a hold rating on shares of Victrex in a research report on Monday, July 22nd. Finally, Numis Securities reissued a hold rating and set a GBX 2,350 ($30.71) price target (down previously from GBX 2,550 ($33.32)) on shares of Victrex in a research report on Monday, May 13th. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of Hold and an average target price of GBX 2,311.36 ($30.20).
Shares of VCT stock opened at GBX 1,955 ($25.55) on Wednesday. The firm has a market cap of $1.69 billion and a PE ratio of 17.00. The company has a 50-day moving average of GBX 1,964.30 and a two-hundred day moving average of GBX 2,180. Victrex has a 1-year low of GBX 1,813.68 ($23.70) and a 1-year high of GBX 3,434 ($44.87).
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, ortho, dental, trauma, knee, cardiovascular, and orthopedic applications. It also offers specialist solutions for medical device manufacturers.
Recommended Story: What is the 52-week high/low?
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.